Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma.

Komiya A, Yasuda K, Nozaki T, Fujiuchi Y, Hayashi SI, Fuse H.

Oncol Lett. 2013 Jan;5(1):53-56. Epub 2012 Oct 25.

2.

[Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].

Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K.

Hinyokika Kiyo. 2007 Jul;53(7):489-92. Japanese.

4.

[Prostatic carcinoma that arose with hearing loss: a case report].

Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K.

Hinyokika Kiyo. 2007 Jun;53(6):413-6. Japanese.

6.
7.
8.

[Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].

Segawa N, Inamoto T, Ibuki N, Mizutani Y, Azuma H, Tsuji M, Katsuoka Y.

Hinyokika Kiyo. 2010 Jan;56(1):49-54. Review. Japanese.

9.

High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.

Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS.

J Urol. 2004 Mar;171(3):1098-104.

PMID:
14767279
10.

High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.

Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, Hinkelbein W, Budach V, Loening SA.

Eur Urol. 2005 Apr;47(4):441-8. Epub 2005 Jan 18.

PMID:
15774239
11.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
13.

Two cases of small cell carcinoma of the prostate.

Okada H, Gotoh A, Ogawa T, Arakawa S, Ohbayashi C, Kamidono S.

Scand J Urol Nephrol. 1996 Dec;30(6):503-8.

PMID:
9008036
14.

Prostatic adenocarcinoma metastases mimicking small cell carcinoma on fine-needle aspiration.

Parwani AV, Ali SZ.

Diagn Cytopathol. 2002 Aug;27(2):75-9.

PMID:
12203872
15.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
17.

Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.

Pellizzon AC, Nadalin W, Salvajoli JV, Fogaroli RC, Novaes PE, Maia MA, Ferrigno R.

Radiother Oncol. 2003 Feb;66(2):167-72.

PMID:
12648788
18.

[Salvage 125I brachytherapy of locally recurrent prostate cancer].

Gesztesi L, Ágoston P, Major T, Gődény M, Andi J, Lengyel Z, Polgár C.

Magy Onkol. 2014 Sep;58(3):219-24. Epub 2014 Aug 12. Hungarian.

20.

High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report.

Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L.

Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):525-33.

PMID:
9635698

Supplemental Content

Support Center